Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Testing effectiveness (Phase 2)Study completedNCT03281369
What this trial is testing

Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Who this might be right for
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Hoffmann-La Roche 214
Large-scale testing (Phase 3)Study completedNCT04499924
What this trial is testing

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
Seagen Inc. 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT03505320
What this trial is testing

Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Who this might be right for
Pharmacokinetics of ZolbetuximabGastric CancerGastro-esophageal Junction (GEJ) Cancer+2 more
Astellas Pharma Global Development, Inc. 143
Early research (Phase 1)Study completedNCT02443324
What this trial is testing

Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Who this might be right for
Gastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionNon-small Cell Lung Cancer+2 more
Eli Lilly and Company 175
Early research (Phase 1)Looking for participantsNCT05365581
What this trial is testing

ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 398
Testing effectiveness (Phase 2)Study completedNCT03941873
What this trial is testing

Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
BeiGene 111
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04032704
What this trial is testing

Ladiratuzumab Vedotin in Advanced Solid Tumors

Who this might be right for
Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
Seagen Inc. 205
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06942767
What this trial is testing

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 100
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07488676
What this trial is testing

ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 150
Testing effectiveness (Phase 2)Ended earlyNCT05207722
What this trial is testing

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Celularity Incorporated 1
Large-scale testing (Phase 3)Looking for participantsNCT06901531
What this trial is testing

Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Not applicableLooking for participantsNCT06902545
What this trial is testing

Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT05702229
What this trial is testing

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
AstraZeneca 163
Early research (Phase 1)Study completedNCT04086758
What this trial is testing

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma China, Inc. 12
Early research (Phase 1)Active Not RecruitingNCT05539430
What this trial is testing

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal-junction CancerEsophageal Cancer+1 more
Legend Biotech USA Inc 56
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06871527
What this trial is testing

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Who this might be right for
Gastric (Stomach) CancerGastric AdenocarcinomaFruquintinib+3 more
Sixth Affiliated Hospital, Sun Yat-sen University 44
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Load More Results
507
500
377